Iconic Labs PLC Issue of Equity and Pay-down of Existing Debt (4530Z)
18 Settembre 2020 - 1:00PM
UK Regulatory
TIDMICON
RNS Number : 4530Z
Iconic Labs PLC
18 September 2020
Iconic Labs Plc ("Iconic Labs" or the "Company")
Issue of Equity and Pay-down of Existing Debt
Iconic Labs Plc (LSE:ICON) (the "Company"), a multi-divisional
new media and technology business, announces that, following the
issuance of the Prospectus on 26(th) March 2020, and pursuant to
the Financing and Settlement Agreement entered into by the Company
and European High Growth Opportunities Securitization Fund (the
"Investor") (see RNS dated 7(th) February 2020), pursuant to which
the Company issued bonds ("Convertible Bonds") convertible into
ordinary shares of GBP0.00001 each in the Company ("Ordinary
Shares") to the investor, the Company has received a notice of
exercise from the Investor in respect of the exercise by the
Investor of its conversion rights under the Convertible Bonds
issued in respect of the sixth and seventh tranches drawn down
under the Financing and Settlement Agreement for the aggregate
principal amount of GBP350,000 resulting in the issue to the
Investor of 5,000,000,000 new Ordinary Shares ("Conversion
Shares").
It should be noted that this is a conversion of Convertible
Bonds already issued pursuant to previous draw downs made by the
Company under the Financing and Settlement Agreement and is not a
request from the Company to draw down anything further under that
facility.
The Company has agreed, subject only to Admission (as defined
below), to issue the Conversion Shares and application will be made
for the Conversion Shares to be listed on the standard segment of
the Official List and to trading on the Main Market for listed
securities of the London Stock Exchange plc ("Admission").
It is expected that Admission will become effective and dealings
in the Conversion Shares will commence on or around 25th September
2020. The Conversion Shares will rank pari passu in all respects
with the existing Ordinary Shares in the Company.
Following Admission of the Conversion Shares, the Company's
enlarged issued share capital will comprise 22,518,082,282 Ordinary
Shares with voting rights. The Company does not hold any shares in
treasury. The figure of 22,518,082,282 Ordinary Shares may be used
by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the Disclosure Guidance and
Transparency Rules of the Financial Conduct Authority.
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information for the purposes of
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public
domain.
**ENDS**
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information for the purposes of
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public
domain.
**ENDS**
For further information, please visit the Company's website
www.iconiclabs.co.uk or contact:
Damon Heath Shard Capital Partners Tel: +44 (0) 20 7186 9950
LLP
Iconic Labs ir@iconiclabs.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEUWRRRRAUKAAR
(END) Dow Jones Newswires
September 18, 2020 07:00 ET (11:00 GMT)
Grafico Azioni Widecells (LSE:WDC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Widecells (LSE:WDC)
Storico
Da Apr 2023 a Apr 2024
